In humans, DRP1 mutation is typically lethal in the first few weeks of life, where patients present with neonatal encephalopathy, microcephaly, demyelination of brain matter, optic atrophy, epilepsy and global developmental delay (EMPF1, MIM #614388) [223,224]. Here, DNM1L is linked to Global developmental delay.